Introduction: Acanthamoeba keratitis is a rare but serious disease and is particularly difficult to treat when the diagnosis is delayed, partly because of the limitations of current therapies. The purpose of our study is to evaluate the anti-amoebic effectiveness of riboflavin and UV-A on Acanthamoeba castellani.
Materials And Methods: We tested the effect of 0.02% chlorhexidine alone (C), the combination of riboflavin 1% and UV-A (UV-A+R), and the combination of the two treatments (R+C+UV-A) on cultures of vegetative and cystic forms of A. castellani. We conducted a parasite count under optical microscopy for each treated area at day 1, 4 and 8.
Results: There was a decrease in the number of cysts for all three treatments (C, UV-A+R, R+C+UV-A). This reduction was greater for the plates treated with R+UV-A (P <0.01 at D8) and those treated with C+R+UV-A (P<0.001 at D8) compared to those exposed to chlorhexidine alone (C). There was no decrease in the number of amoebic trophozoites for the three treatments (C, UV-A+R, R+C+UV-A), but encystment was observed.
Discussion: Given the in vitro efficacy of riboflavin combined with UV-A against cystic forms of A. castellani and excellent in vivo tolerance of the procedure, the treatment of acanthamoeba keratitis might be improved by this new therapeutic approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfo.2014.09.013 | DOI Listing |
Eye Vis (Lond)
January 2025
ELZA Institute AG, Bahnhofstrasse 15, 8001, Zurich, Switzerland.
Background: Acanthamoeba keratitis (AK) is the most challenging corneal infection to treat, with conventional therapies often proving ineffective. While photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) with riboflavin/UV-A has shown success in treating bacterial and fungal keratitis, and PACK-CXL with rose bengal/green light has demonstrated promise in fungal keratitis, neither approach has been shown to effectively eradicate AK. This case study explores a novel combined same-session treatment approach using both riboflavin/UV-A and rose bengal/green light in a single procedure.
View Article and Find Full Text PDFExp Eye Res
December 2024
Aravind Medical Research Foundation, Madurai, Tamil Nadu, India. Electronic address:
The need for better and simpler alternative crosslinking strategies to treat keratoconus (KC) is becoming essential as there is only a single approved way to treat it. Recently, conventional UV-A Riboflavin crosslinking is proven to have some disadvantages such as causing damage to the corneal endothelium and inducing keratocyte apoptosis. A chemical cross-linker (CXL) using carbodiimide chemistry and an octanedioic acid spacer is found effective in stiffening the cornea and has the potential to be developed as an alternative therapy to halt KC progression.
View Article and Find Full Text PDFProg Retin Eye Res
January 2025
ELZA Institute, Webereistrasse 2, CH-8953, Dietikon, Switzerland; Laboratory for Ocular Cell Biology, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland; Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, CH-1206, Geneva, Switzerland. Electronic address:
First introduced over 20 years ago as a treatment for progressive keratoconus, the original "Dresden" corneal cross-linking (CXL) protocol involved riboflavin saturation of the stroma, followed by 30 min of 3 mW/cm-intensity ultraviolet-A (UV-A) irradiation. This procedure generates reactive oxygen species (ROS) that cross-link stromal molecules, thereby stiffening the cornea and counteracting the ectasia-induced weakening. Due to their large size, riboflavin molecules cannot readily pass through the corneal epithelial cell tight junctions; thus, epithelial debridement was performed.
View Article and Find Full Text PDFJ Cataract Refract Surg
December 2024
ELZA Institute, Dietikon, Switzerland.
Purpose: To investigate the light transmission (LT) of UV-A and green light through infected corneas saturated with riboflavin or rose bengal in an ex vivo porcine model for infectious keratitis.
Setting: University of Zurich and EMPA.
Design: Laboratory study.
J Biophotonics
December 2024
Studio Italiano di Oftalmologia, Rome, Italy.
This study investigated the effect of a theranostic-guided UV-A light corneal photo-reshaping technique on corneal elevation and wavefront aberration (WA) in human donor eyes. A specialized platform, combining UV-A light with corneal iontophoresis for controlled, patterned, riboflavin delivery, was used for both distribution assessment and concentration-driven photopolymerization of corneal proteins. In all cases, a consistent riboflavin concentration gradient, with lower levels in the central prepupillary zone, was recorded.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!